View Item 

Show simple item record

Differentiation of the Low‐Molecular‐Weight Heparins
dc.contributor.authorRacine, Ericen_US
dc.date.accessioned2012-03-16T16:00:59Z
dc.date.available2012-03-16T16:00:59Z
dc.date.issued2001-06en_US
dc.identifier.citationRacine, Eric (2001). "Differentiation of the Low‐Molecular‐Weight Heparins." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21(6P2): 62S-70S. <http://hdl.handle.net/2027.42/90369>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90369
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleDifferentiation of the Low‐Molecular‐Weight Heparinsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumPharmacy Administration, Harper University Hospital, Detroit Medical Center; the College of Pharmacy and Allied Health Professions, Wayne State University; and the College of Pharmacy, University of Michigan, Detroit, Michiganen_US
dc.identifier.pmid11401195en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90369/1/phco.21.8.62S.34594.pdf
dc.identifier.doi10.1592/phco.21.8.62S.34594en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceLeizorovicz A. Comparison of the efficacy and safety of low‐molecular‐weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: an updated meta‐analysis. Drugs 1996; 52 ( suppl 7: 30 – 7.en_US
dc.identifier.citedreferenceCairns J.A., Theroux P., Lewis H.D., et al. Antithrombotic agents in coronary artery disease. Chest 2001; 119: 228S – 52.en_US
dc.identifier.citedreferenceMonreal M., Lafoz E., Navarro A., et al. A prospective double‐blind trial of a low molecular weight heparin once daily compared with conventional low‐dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fractures. J Trauma 1989; 26 ( 6P2 ): 873 – 5.en_US
dc.identifier.citedreferenceGould M., Dembitzer A., Doyle R., et al. Low‐molecular‐weight heparins compared with unfractionated heparin for the treatment of acute deep venous thrombosis: a meta‐analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800 – 9.en_US
dc.identifier.citedreferenceDolovich L., Ginsberg J.S., Douketis J., et al. A meta‐analysis comparing low‐molecular‐weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000; 160: 181 – 8.en_US
dc.identifier.citedreferenceLensing A., Prins M., Davidson B., et al. Treatment of deep venous thrombosis with low‐molecular‐weight heparins: a meta analysis. Arch Intern Med 1995; 155: 601 – 7.en_US
dc.identifier.citedreferenceLeizorovicz A., Simonneau G., Decousus H., et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta‐analysis. BMJ 1994; 309: 299 – 304.en_US
dc.identifier.citedreferenceSiragusa S., Cosmi B., Piovella F., et al. Low‐molecular‐weight heparin and unfractionated heparin in the treatment of patients with acute venous thromboembolism: result of a meta‐analysis. Am J Med 1996; 100: 269 – 77.en_US
dc.identifier.citedreferenceHull R.D., Raskob G.E., Pineo G., et al. Subcutaneous low‐molecular‐weight heparin compared with continuous intravenous heparin in the treatment of proximal‐vein thrombosis. N Engl J Med 1992; 326: 975 – 82.en_US
dc.identifier.citedreferenceSimmoneau G., Sors J., Charbonnier B., et al. A comparison of low‐molecular‐weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663 – 9.en_US
dc.identifier.citedreferenceMerli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191 – 201.en_US
dc.identifier.citedreferencePartsch H., Kechavaarz B., Mostbeck A., et al. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once‐ or twice‐daily low‐molecular‐weight heparin. J Vas Surg 1996; 24 ( 5 ): 774 – 82.en_US
dc.identifier.citedreferenceNightingale S.L. Food and Drug Administration [letter]. JAMA 1993; 270: 1672.en_US
dc.identifier.citedreferenceAntman E.M., Fox K.M. Guidelines for the diagnosis and management of unstable angina and non‐Q‐wave myocardial infarction: proposed revisions. International cardiology forum. Am Heart J 2000; 139: 461 – 75.en_US
dc.identifier.citedreferenceRyan T., Antman E., Brooks N. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on management of acute myocardial infarction). J Am Coll Cardiol 1999; 3: 890 – 911.en_US
dc.identifier.citedreferenceWeitz J.I. Low‐molecular‐weight heparins. N Engl J Med 1997; 337: 688 – 98.en_US
dc.identifier.citedreferenceHirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low‐molecular‐weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S – 94.en_US
dc.identifier.citedreferenceLinhardt R., Gunay N. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 ( suppl 3: 5 – 25.en_US
dc.identifier.citedreferencePharmacia & Upjohn. Fragmin (dalteparin) package insert. Kalamazoo, MI; May 1999.en_US
dc.identifier.citedreferenceAventis Pharmaceuticals. Lovenox (enoxaparin) package insert. Parsippany, NJ; January 2001.en_US
dc.identifier.citedreferenceDupont Pharma. Innohep (tinzaparin) package insert. Wilmington, DE; July 2000.en_US
dc.identifier.citedreferenceFareed J., Jeske W., Hoppensteadt D., et al. Are the available low‐molecular weight heparin preparations the same? Semin Thromb Hemost 1996; 22 ( suppl 1: 77 – 91.en_US
dc.identifier.citedreferenceCasu B., Torri G. Structural characterization of low‐molecular weight heparins. Semin Thromb Hemost 1999; 25 ( suppl 3: 17 – 25.en_US
dc.identifier.citedreferenceSamama M., Gerotziafas G.T. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 ( suppl 1: 31 – 8.en_US
dc.identifier.citedreferenceCollignon F., Frydman A., Caplain H., et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins—dalteparin, enoxaparin, and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73 ( 4 ): 630 – 40.en_US
dc.identifier.citedreferenceEriksson B.I., Soderberg K., Widlund L., et al. A comparative study of three low‐molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398 – 401.en_US
dc.identifier.citedreferenceMammen E.F., Arcelus J., Messmore H. Clinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999; 25 ( suppl 3: 135 – 44.en_US
dc.identifier.citedreferenceBroze G.J. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90 – 3.en_US
dc.identifier.citedreferenceFareed J., Fu K., Yang L.H., et al. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 1999; 25 ( suppl 3: 51 – 5.en_US
dc.identifier.citedreferenceZacharski L.R., Ornstein D.L. Heparin and cancer. Thromb Haemost 1998; 80: 10 – 23.en_US
dc.identifier.citedreferenceFay P.J., Coumans J.V., Walker F.J. vWF mediates protection of factor VIII from activated protein C‐catalyzed inactivation. J Biol Chem 1991; 266: 2172 – 7.en_US
dc.identifier.citedreferenceMann K.G. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165 – 74.en_US
dc.identifier.citedreferenceMontalescot G., Collet J.P., Lison L., et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110 – 14.en_US
dc.identifier.citedreferenceMontalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998; 98: 287 – 9.en_US
dc.identifier.citedreferenceKlein W., Buchwald A., Stuart E.H., et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease (FRIC) Trial. Circulation 1997; 96: 61 – 8.en_US
dc.identifier.citedreferenceCohen M., Demers C., Enrique P., et al. A comparison of low‐molecular‐weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447 – 52.en_US
dc.identifier.citedreferenceAntman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non‐Q‐wave myocardial infarction (TIMI) −11B trial. Circulation 1999; 337: 447 – 52.en_US
dc.identifier.citedreferenceAntman E.M., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non‐Q‐wave myocardial infarction: TIMI 11B‐ESSENCE meta‐analysis. Circulation 1999; 100: 1602 – 8.en_US
dc.identifier.citedreferenceBozovich G.E., Gurfinkel E.P., Antman E.M., et al. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non‐Q‐wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J 2000; 140: 637 – 42.en_US
dc.identifier.citedreferenceDowning L.J., Farris D.M., Hawley A.E., et al. Low molecular weight heparins are anti‐thrombotic and anti‐inflammatory during stasis induced venous thrombosis. Presented at the 13th annual meeting of the American Venous Forum, Fort Myers, Florida, February 2225, 2001.en_US
dc.identifier.citedreferenceGeerts W.H., Heit J.A., Clagett G.P., et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S – 75.en_US
dc.identifier.citedreferenceHyers T.M., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S – 93.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.21.8.62S.34594.pdf
Size:
63.43KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.